Blestriarene C exerts an inhibitory effect on triple-negative breast cancer through multiple signaling pathways.

ABSTRACT:

Introduction

Breast cancer is the most common cancer worldwide, the leading cause of cancer death in women, and the fifth leading cause of cancer death. Triple negative breast cancer (TNBC), with high metastasis and mortality rates, is the most challenging subtype in breast cancer treatment. There is an urgent need to develop anti-TNBC drugs with significant efficacy, low side effects and good availability. In early drug screening, blestriarene C was found to have inhibitory effects on TNBC cells. In this article, we further explore the mechanisms associated with blestriarene C for breast cancer.

Methods

In this article, we take the approach of network pharmacology combined with in vivo and in vitro experiments. Network pharmacology analysis was used to predict the active co

SUBMITTER: An J 

PROVIDER: S-EPMC11534688 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature